Prudential PLC Increases Stake in DaVita Inc. (NYSE:DVA)

Prudential PLC increased its position in shares of DaVita Inc. (NYSE:DVA) by 40.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,980 shares of the company’s stock after purchasing an additional 4,633 shares during the period. Prudential PLC’s holdings in DaVita were worth $2,214,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Blue Trust Inc. boosted its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the period. Newbridge Financial Services Group Inc. bought a new position in DaVita in the 4th quarter valued at $30,000. Principal Securities Inc. purchased a new stake in DaVita in the fourth quarter worth $37,000. Family Firm Inc. bought a new stake in shares of DaVita during the second quarter worth $43,000. Finally, Versant Capital Management Inc boosted its stake in shares of DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DaVita stock opened at $153.99 on Thursday. The company has a market capitalization of $12.92 billion, a PE ratio of 17.50, a P/E/G ratio of 0.86 and a beta of 0.86. The company has a 50-day simple moving average of $144.24 and a two-hundred day simple moving average of $139.43. DaVita Inc. has a one year low of $71.51 and a one year high of $156.44. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. During the same quarter in the previous year, the business posted $2.08 EPS. DaVita’s revenue was up 6.2% on a year-over-year basis. Research analysts expect that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the sale, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Insiders have sold a total of 113,601 shares of company stock worth $17,525,449 in the last ninety days. 2.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on DVA. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial lifted their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, TD Cowen raised their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.